Adage Capital Partners
FDMT icon

Adage Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Adage Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9M Buy
1,605,156
+370,000
+30% +$3.22M 0.02% 578
2025
Q4 		$9.26M Buy
1,235,156
+1,060,156
+606% +$10.8M 0.01% 681
2025
Q3 		$1.52M Buy
+175,000
New +$1.05M ﹤0.01% 822

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Adage Capital Partners's FDMT Position: Q1 2026 in Review

Adage Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 30% in Q1 2026, buying an estimated $3.22M and bringing the position to 1,605,156 shares worth $14.9M. The position accounts for 0.02% of the portfolio, ranked #578.

Adage Capital Partners first reported a position in FDMT in Q3 2025 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Adage Capital Partners held 1,605,156 shares of 4D Molecular Therapeutics worth $14.9M as of Q1 2026.
  • Adage Capital Partners bought 370,000 4D Molecular Therapeutics shares in Q1 2026, an estimated $3.22M.
  • 4D Molecular Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #578 holding.
  • Adage Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.